Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20093 ± adebrelimab in advanced non-squamous NSCLC after platinum and PD-(L)1 therapy
CTR20263186Phase 2Active
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Aug 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of risvutatug rezetecan in non-small cell lung cancer (NSCLC), sponsored by Hansoh Pharmaceutical Group. Started Aug 2026; status: active.
02
Drugs
risvutatug rezetecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20263186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263186.